A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Phase 3
Active, not recruiting
- Conditions
- Patient PreferenceLeukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesLeukemia, Myeloid, Acute
- Interventions
- Drug: Oral decitabine/cedazuridine
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Otsuka Australia Pharmaceutical Pty Ltd
- Target Recruit Count
- 13
- Registration Number
- NCT05883956
- Locations
- 🇦🇺
Calvary Mater Newcastle, Newcastle, New South Wales, Australia
🇦🇺Pindara Private Hospital, Benowa, Queensland, Australia
🇦🇺Townsville Hospital, Townsville, Queensland, Australia
Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire
Completed
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- Other: Patient Treatment Preference Myelodysplasia QuestionnaireOther: Carer Treatment Preference Myelodysplasia QuestionnaireOther: Clinician Treatment Preference Myelodysplasia Questionnaire
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Otsuka Australia Pharmaceutical Pty Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT05817331
- Locations
- 🇦🇺
Calvary Mater Newcastle, Newcastle, New South Wales, Australia
© Copyright 2025. All Rights Reserved by MedPath